SenesTech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 8, 2016, reports on a material definitive agreement entered into by SenesTech, Inc. The filing details a public offering of common stock that closed on December 13, 2016. The company is based in Flagstaff, Arizona, and focuses on the development and commercialization of pest control products, specifically its first product candidate, ContraPest.
Key Financial Metrics and Transaction Details
- Offering Size: 1,875,000 shares of common stock (Initial Securities).
- Public Offering Price: $8.00 per share.
- Net Proceeds to Company: Approximately $13.3 million (after underwriting discounts, commissions, and estimated expenses).
- Underwriting Discount: Net price to the company was $7.44 per share.
- Warrant Issuance: A warrant issued to Roth Capital Partners, LLC for up to 187,500 shares at an exercise price of $9.60 per share (120% of offering price).
- Options: Underwriters hold a 30-day option to purchase up to 31,250 additional shares from the Company and 250,000 additional shares from Selling Stockholders.
Material Changes and Use of Proceeds
The primary material change is the capital raise via the equity offering. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period, as this is a transaction report rather than a periodic financial statement. The net proceeds of approximately $13.3 million are designated for the following uses:
- Commercialization and launch of ContraPest in the United States and other countries.
- Seeking regulatory approval for ContraPest.
- Further development of ContraPest and other product candidates.
- Capital expenditures for manufacturing ContraPest.
- Funding a cash payment to the holder of Series A convertible preferred stock to waive accrued dividends and convert shares to common stock.
- Working capital and general corporate purposes.
Outlook, Risks, and Contingencies
Management intends to utilize the capital to advance the commercialization of ContraPest. The filing notes that the Warrant and underlying shares are subject to a 180-day lock-up period. The exercise price and share count of the Warrant are subject to adjustment in the event of stock dividends, extraordinary cash dividends, or recapitalization. The Underwriting Agreement includes customary indemnification provisions where the Company and Selling Stockholders indemnify the Underwriters against certain liabilities.
Key Facts for Investor Verification
- Verify the actual closing date and final number of shares sold, including any exercise of the 30-day option by underwriters.
- Confirm the specific amount paid to the Series A convertible preferred stockholder to waive dividends and convert shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Warrant (Exhibit 4.2) for detailed terms regarding lock-up periods and adjustment mechanisms.
- Monitor the company's progress on regulatory approval and commercial launch of ContraPest as the primary use of the raised capital.